MedTrace Logo

An Observational Study of Vonicog Alfa (rVWF) in Pediatric Participants With Von Willebrand Disease (vWD)

NCT07404644 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 13

Last updated 2026-02-23

No results posted yet for this study

Summary

This study is conducted in Japan of vonicog alfa (rVWF) used to treat pediatric participants with Von Willebrand Disease (vWD).

The main aim of the study is to evaluate adverse drug reaction and effectiveness of vonicog alfa (rVWF).

During the study, pediatric participants with vWD will be administered with rVWF under routine normal practice. The investigators will evaluate adverse events due to rVWF for 1 year from the start of drug administration.

The study sponsor will not be involved in how the participants are administered but will be recorded what happens during the study.

Conditions

  • Von Willebrand Disease (vWD)

Interventions

DRUG

vonicog alfa (rVWF)

rVWF administered by intravenous injection.

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Eligibility

Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-19
Primary Completion
2031-05-30
Completion
2031-05-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07404644 on ClinicalTrials.gov